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Abstract
Background: The use of cardiac output monitoring to guide intra-venous fluid and inotropic therapies may
improve peri-operative outcomes, but uncertainty exists regarding clinical effectiveness and robust cost-
effectiveness evidence is lacking. The objective of the study was to evaluate the cost-effectiveness of peri-operative
cardiac output-guided haemodynamic therapy versus usual care in high-risk patients undergoing major
gastrointestinal surgery.
Methods: The study undertook a cost-effectiveness analysis using data from a multi-centre randomised trial that
recruited patients from 17 hospitals in the United Kingdom. The trial compared cardiac output-guided, haemodynamic
therapy algorithm for intra-venous fluid and inotrope (dopexamine) infusion during and 6 h following surgery, with
usual care. Resource use and outcome data on 734 high-risk trial patients aged over 50 years undergoing major
gastrointestinal surgery were used to report cost-effectiveness at 6 months and to project lifetime cost-effectiveness.
The cost-effectiveness analysis used information on health-related quality of life (QoL) at randomisation, 30 days, and
6 months combined with information on vital status to report quality-adjusted life years (QALYs). Each QALY was
valued using the National Institute for Health and Care Excellence (NICE) recommended threshold of willingness to pay
(£20,000 per QALY) in conjunction with the costs of each group to report the incremental net monetary benefits (INB)
of the treatment algorithm versus usual care.
Results: The mean [SD] quality of life at 30 days and 6 months was similar between the treatment groups (at
6 months, intervention group 0.73 [0.28] versus usual care group 0.71 [0.30]; mean gain 0.03 [95 % confidence interval
(CI) −0.01 to 0.08]). At 6 months, survival, mean QALYs and mean healthcare costs (intervention group £8574 versus
usual care group £8974) were also similar. At the cost-effectiveness threshold of £20,000 per QALY gained, the
incremental net benefit of haemodynamic therapy over the patients’ lifetime was positive (£4168 [95 % CI −£3063 to
£11,398]). This corresponds to an 87 % probability that this intervention is cost-effective.
Conclusions: Cardiac output-guided haemodynamic therapy algorithm was associated with an average cost reduction
and improvement in QALY and is likely to be cost-effective. Further research is needed to confirm the clinical and cost-
effectiveness of this treatment.
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Background
More than 230 million surgical procedures are per-
formed worldwide each year with an estimated mortality
between 1 and 4 % (Pearse et al. 2012; Weiser et al.
2008). However, post-operative complications and death
are much more frequent among high-risk patients, those
who are older, those who have co-morbid disease and
those who undergo major surgery. Importantly, patients
who develop complications, but survive to leave hospital,
experience a reduction in long-term survival (Pearse et
al. 2011; Khuri et al. 2005). Post-operative complications
increase healthcare costs significantly as a result of add-
itional treatment and prolonged hospitals stays (Boltz et
al. 2011). Implementation of new treatment strategies
for this patient group therefore requires evidence of
cost-effectiveness as well as clinical effectiveness.
The dose of intra-venous fluid has an important effect
on patient outcomes following major gastrointestinal
surgery. However, fluid is widely prescribed according to
subjective criteria leading to wide variation in clinical
practice (Pearse and Ackland 2012). One potential solu-
tion to this problem is the use of cardiac output moni-
toring to guide administration of intra-venous fluid and
inotropic agents (Pearse and Ackland 2012). This ap-
proach has been recommended in a report commis-
sioned by the Centers for Medicare and Medicaid
Services in the United States of America (USA) (Agency
for Healthcare Research and Quality 2007) and by the
National Institute for Health and Care Excellence (NICE)
in the United Kingdom (UK) (National Institute for
Health and Clinical Excellence 2011). Hospitals in the UK
National Health Service (NHS) receive a Commissioning
for Quality and Innovation payment for each patient
treated. These national policy recommendations are based
on very limited health economic data. Meanwhile, the
findings of a recent Cochrane review suggest that the
benefit associated with this treatment may be more mar-
ginal than previously believed (Grocott et al. 2012).
In this context, the OPTIMISE trial was conducted to
evaluate the clinical effectiveness of cardiac output mon-
itoring to guide administration of intra-venous fluid and
inotropic drugs as part of a haemodynamic therapy al-
gorithm in a large, pragmatic, multi-centre and rando-
mised controlled trial in high-risk patients undergoing
major gastrointestinal surgery (Pearse et al. 2014). The
aim of this analysis was to confirm whether a cardiac
output-guided haemodynamic therapy algorithm is
cost-effective in high-risk patients undergoing major
gastrointestinal surgery.
Methods
Ethics, consent and permissions
The OPTIMISE trial protocol version 1.8 was approved
by the East London and City Research Ethics Committee
(chair: Dr A. Tucker) on 7 December 2009 (reference:
09/H0703/23) and by the Medical and Healthcare prod-
ucts Regulatory Agency (reference: 2009-009596-35). Writ-
ten informed consent was obtained from all patients prior
to inclusion in the trial.
Setting, patients and clinical management
OPTIMISE was a pragmatic, multi-centre, randomised
and observer-blinded trial conducted in 17 NHS hospi-
tals in the UK. The trial findings, including the study
protocol, are presented in detail elsewhere (Pearse et al.
2014). Adult patients, aged 50 years or over, undergoing
major gastrointestinal surgery were eligible for recruit-
ment provided they satisfied one or more predefined
high-risk criteria. The intervention period commenced
with induction of anaesthesia and continued until 6 hours
after surgery was completed. All patients received stand-
ard measures to maintain oxygenation (SpO2 ≥ 94 %),
haemoglobin (>8 g/dl), core temperature (37 °C), and
heart rate (<100 bpm). Five percent of dextrose was ad-
ministered at 1 ml/kg/h to satisfy maintenance fluid re-
quirements with additional fluid administered at the
discretion of the treating clinician guided by pulse rate, ar-
terial pressure, urine output, core-peripheral temperature
gradient, serum lactate and base excess. Mean arterial
pressure was maintained between 60 and 100 mmHg
using an alpha adrenoceptor agonist or vasodilator as re-
quired. Post-operative analgesia was provided by epidural
infusion (bupivacaine and fentanyl) or intra-venous infu-
sion (morphine or fentanyl). In addition, intervention
group patients received intra-venous fluid and inotropic
therapy guided by a haemodynamic therapy algorithm in-
formed by cardiac output monitoring (LiDCOrapid,
LiDCO Ltd, UK). This algorithm included the use of
250 ml intra-venous fluid challenges with colloid solution,
as required, in order to achieve and maintain the maximal
value of stroke volume. No attempt was made to stand-
ardise the choice of colloid solution. The patients in the
intervention group also received an intra-venous infusion
of dopexamine at a fixed rate of 0.5 μg/kg/min (Cephalon,
Welwyn Garden City, UK) either through a peripheral or
central venous catheter. The dose of dopexamine was re-
duced if the heart rate increased above 120 % of baseline
value or 100 bpm (whichever was greater) for more than
30 min despite adequate anaesthesia and analgesia. If the
heart rate did not decrease despite dose reduction, then
the dopexamine infusion was discontinued. The patients
in the control group received usual clinical care; however,
the use of a dynamic central venous pressure target was
recommended. Cardiac output monitoring was not used
in the control group unless specifically requested by clin-
ical staff because of patient deterioration. All other man-
agement decisions were taken by senior clinicians who
retained the discretion to alter any aspect of patient care.
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Six-month outcomes
Health outcome is reported in terms of quality-adjusted
life years (QALYs), which incorporate the effects of the
intervention on both length of survival and quality of
life. During the 6-month follow-up period, survival data
were recorded by trial investigators and subsequently
linked with death registrations from the Health and
Social Care Information Centre (HSCIC) to give survival
status and date of death for patients discharged from
hospital. The patients (or their carers) were asked to
complete a generic health-related quality of life ques-
tionnaire, the EuroQol (5-dimension 3-level version;
EQ-5D-3L), at randomisation, 30 days and 6 months
after surgery. The EQ-5D health profiles of each patient
were then converted into a single summary index by ap-
plying a formula that attaches a weighting to the levels
in each dimension. Patients’ EQ-5D profiles were com-
bined with health state preference values from the UK
general population (Dolan et al. 1999), to derive an EQ-
5D utility index score anchored on a scale from 0
(death) to 1 (perfect health). QALYs were calculated by
using the area under the curve method whereby each
patient’s survival times is weighted by their correspond-
ing quality of life scores at each time point (Manca et al.
2005). Patients who died between 1 and 6 months after
randomisation were assigned zero quality of life scores
at the corresponding time point. The base case analysis
used the quality of life score at day 30 as the baseline
measure rather than the score at randomisation, which
for both arms may reflect the surgery itself.
Healthcare resource use and costs
Resource use data were collected prospectively for each
patient including information on the surgical procedure,
trial intervention, length of stay in critical care and on
the surgical ward. The unit costs of the surgical proce-
dures were estimated from the NHS Payment by Results
database (Department of Health 2013). These reference
costs provide an average cost of both the surgery and
hospital stay. To avoid double counting associated with
costs of hospital stay, the costs of average length of stay
and of 1 day in a post-anaesthetic recovery unit were
subtracted from the national average unit cost, for each
eligible surgical procedure. Critical care bed days were
costed separately according to the level of care received
(levels 2 and 3). No additional staff costs were consid-
ered because the intervention was specifically designed
for delivery with existing peri-operative care resources.
The costs of cardiac output monitoring equipment were
obtained from the manufacturer (personal communica-
tion). Use of transfused blood products and intra-venous
fluids was recorded for each patient and costed using
unit costs provided by the NHS Blood and Transplant
and the British National Formulary (Additional file 1:
Table S1) (NHS Blood and Transplant 2013; Joint
Formulary Committee. British National Formulary
(online) London: BMJ Group and Pharmaceutical Press
(accessed on 25th October 2013)). All unit costs were
reported at 2012–2013 price levels.
Six-month cost-effectiveness analysis
Cost-effectiveness analysis is based on the recognition
that evidence of clinical effectiveness of interventions is
necessary but not sufficient for decision making for
adopting interventions. Here, it is essential to estimate
the extent to which interventions represent value for
money. The aim of cost-effectiveness analysis is to esti-
mate the effect of a new treatment on the joint distribu-
tion of costs and effects. This approach can estimate the
overall value of the intervention rather than accepting or
rejecting value of intervention on the basis of individual
tests of significance on costs and effects.
The cost-effectiveness analysis was conducted from an
NHS perspective, using bivariate regression methods to
correlate between costs and outcomes to report the
mean (95 % confidence intervals) incremental costs and
QALYs in the intervention group versus the usual care
group. It needs to be highlighted that for economic ana-
lysis, the mean estimate is most required for decision-
makers who will be interested in calculating the total
costs of adopting an intervention and the total effects re-
ceived in return for incurring these costs. The regression
model was adjusted for age, gender, urgency of surgery,
surgical procedure, location following surgery (critical
care or standard ward), American Society of Anesthesi-
ologists (ASA) grade, renal impairment, diabetes melli-
tus, risk factors for cardiac and/or respiratory disease,
EQ-5D score at randomisation and included a random
effect for each site. Pre-specified sub-group analyses
were conducted according to urgency of surgery, surgi-
cal procedure category, and timing of patient recruit-
ment (first ten patients recruited at each site versus all
subsequent patients).
Cost-effectiveness is reported in terms of the incre-
mental net monetary benefit (National Institute for
Health and Care Excellence 2013), by valuing each incre-
mental QALY at the relevant UK (NICE) willingness to
pay threshold of £20,000 and subtracting incremental
costs. A positive value of incremental net monetary benefit
suggests an intervention is cost-effective. Cost-effectiveness
acceptability curves were constructed by calculating the
probability that the OPTIMISE intervention was cost-
effective at different levels of willingness to pay for a
QALY gain (from £0 to £50,000 per QALY gained)
(Fenwick et al. 2004). Missing data were addressed
through multiple imputation assuming that data were
missing at random (Rubin 1987). Analyses were per-
formed using STATA/IC version 13 and R version 3.0.2.
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Lifetime cost-effectiveness analysis
The long-term survival for each patient was calculated
from observed survival within the first 6 months follow-
ing surgery and from the predicted survival after
6 months using HSCIC data. Life expectancy after
6 months was predicted for each patient by applying
age-gender adjusted excess death rates for OPTIMISE
patients who survived beyond 6 months compared to
the age-gender-matched UK general population (Office
of National Statistics 2008). The most plausible long-
term survival extrapolation was selected by comparing
the relative goodness of fit and excess death rates of al-
ternative parametric survival functions (Latimer 2013).
To predict long-term quality of life, we used the mean
value at 6 months for patients aged 72 years (median
age of OPTIMISE patients). We predicted mean quality
of life between year 1 and year 2 with a linear
interpolation, such that after 2 years, the mean value for
the OPTIMISE patients was similar to that of the age-
matched general population. We then combined these
predicted values of life expectancy and quality of life to
calculate the projected lifetime QALYs. Lifetime incre-
mental costs, incremental net monetary benefit and
cost-effectiveness acceptability curves were then calcu-
lated using the same methods described for the 6-month
analysis. Lifetime QALYs were discounted at 3.5 %. Re-
sults were reported over all the patients randomised and
for the above pre-specified subgroups.
Value of information analysis
Value of information analysis provides useful informa-
tion about the economic value of further research into a
given question. Value of information approaches require
the estimation of the expected costs of continued uncer-
tainty about the treatment decision (in this case, whether
to introduce the haemodynamic algorithm) and then the
calculation of the expected value of perfect information
(EVPI), that is, of the evidence required to eliminate this
uncertainty. EVPI is also the maximum that a decision-
maker would be willing to pay for additional future re-
search to inform this decision (Claxton 1999; Claxton
and Posnett 1996). Here, the EVPI was calculated ac-
cording to the cost-effectiveness results and according to
the size of the eligible patient population estimated from
the NHS Hospital Episodes Statistics database. We also
assumed that future patients could be expected to bene-
fit from the algorithm over 5 years and that the incre-
mental net monetary benefit was normally distributed
(Briggs et al. 2006), and we applied a 3.5 % discount rate
(Claxton 1999).
Sensitivity analyses
The following sensitivity analyses were performed to
evaluate assumptions made in the primary analysis:
(a)Analysis including additional costs of a level 2
critical care bed day and 1 h of recovery nurse time
for patients who were not transferred directly to
critical care after surgery.
(b)Analysis including 4.5 h of additional nurse time
after surgery to deliver the intervention.
(c)Analysis using EQ-5D values measured at
randomisation as opposed to 30 days after surgery.
(d)Analysis estimating QALY for decedents for the time
those patients were living. For decedents between
randomisation and 1 month, a linear interpolation
was applied between the baseline EQ-5D and the
date of death when a zero EQ-5D score was applied.
For decedents between 1 and 6 months where an
EQ-5D score at 1 month was available, a linear
interpolation was applied between the 1-month EQ-
5D and the date of death when a zero EQ-5D score
was applied.
(e)Analysis assuming quality of life remained
unchanged after 6 months.
(f ) Analysis estimating lifetime survival by applying the
most plausible parametric function to the observed
data for those surviving beyond 6 months following
surgery, instead of assuming survival, was the same
as that of the age and gender-matched general
population (Latimer 2011).
Results
Baseline characteristics and 6-month outcomes
Of 734 patients randomised to OPTIMISE, one was ran-
domised in error and excluded from the analysis. A fur-
ther seven patients formally withdrew from the trial, and
two patients were lost to follow-up. Baseline risk factors
and quality of life were similar between groups (Table 1).
There was no significant difference in survival at 6 months
(Table 2). The mean EQ-5D-3L utility index score for sur-
vivors at month 1 and month 6, and the mean QALYs up
to 6 months were similar between groups (Table 2).
Healthcare resource use and costs
The mean total healthcare costs were similar in the two
groups (intervention group £8574 versus usual care group
£8974) (Table 3). The average cost of haemodynamic ther-
apy during the intervention period was greater in the
intervention group compared to the usual care but this
cost was small compared to the total healthcare costs
(intervention group £230 versus usual care group £63)
(Fig. 1 and Additional file 1: Table S2). Whilst critical care
utilisation and mean length of hospital stay (intervention
group 13.5 days versus usual care group 14.9 days) did not
differ statistically, these did contribute to the non-
significant difference in total healthcare costs which more
than offset the cost of the trial intervention.
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Six-month cost-effectiveness analysis
At 6 months following surgery, the mean incremental
costs of the intervention were negative (−£404, 95 %
confidence interval (CI) −£1313 to £505), indicating that
the average costs of the overall package of care were less
for the trial invention versus the usual care arm (Table 4).
When the QALY gain of 0.01 was valued at willingness
to pay of £20,000 per QALY and the incremental cost
subtracted, the incremental net monetary benefit was
£580 (95 % CI −£378 to £1538) per patient (Additional
file 1: Figure S1). Sub-group analyses revealed no differ-
ence in the effect of the intervention on 6-month net
monetary benefits according to either urgency or type of
surgery (Additional file 1: Table S3). However, in the




(n = 368) (n = 365)
Age (year) 71.26 (8.4) 72.20 (8.6)
Gender, male 237 (64.4) 229 (62.7)
Urgency of surgery
Elective surgery 356 (96.7) 352 (96.4)
Non-elective surgery 12 (3.3) 13 (3.6)
Surgery†
Upper gastrointestinal 108 (29.4) 111 (30.4)
Lower gastrointestinal 168 (45.7) 165 (45.2)
Small bowel +/− pancreas 86 (23.4) 82 (22.5)
Urological or gynaecological involving gut 5 (1.4) 4 (1.1)
No surgery performed 1 (0.3) 3 (0.8)
ASA gradea
1 22 (6.0) 27 (7.4)
2 200 (54.4) 174 (47.7)
3 143 (38.9) 155 (42.5)
4 3 (0.8) 9 (2.5)
Location following surgery
Critical care level 2 258 (70.1) 246 (67.4)
Critical care level 3 42 (11.4) 40 (11.0)
Post-anaesthetic recovery unit 10 (2.7) 9 (2.5)
General ward 58 (15.8) 70 (19.2)
Renal impairment 26 (7.1) 12 (3.3)
Diabetes mellitus 57 (15.5) 65 (17.8)
Risk factor for cardiac or respiratory disease 118 (32.1) 118 (32.3)
Baseline quality of life scorea 0.78 (0.2) 0.77 (0.3)
Data presented as mean (SD) or n (%)
aSummaries presented after multiple imputation. †Planned surgical procedure assumed when type of surgery performed was missing for one case
Table 2 Mortality, EuroQol 5-dimension (EQ-5D) and quality-adjusted life years (QALY) up to 6 months for trial participants
Peri-operative cardiac output-guided
haemodynamic therapy algorithm
Usual care Incremental effecta
(n = 368) (n = 365)
6-month mortality 28 (7.61) 42 (11.51) −0.40 (−0.39 to 1.14)
EQ-5D for survivors at month 1 0.66 (0.30) 0.63 (0.31) 0.02 (−0.02 to 0.06)
EQ-5D for survivors at month 6 0.73 (0.28) 0.71 (0.30) 0.03 (−0.01 to 0.08)
QALY up to 6 months 0.37 (0.11) 0.36 (0.12) 0.01 (0.00 to 0.02)
Data presented as mean (SD) or mean (95 % confidence intervals)
aOdds ratio for death, incremental for other estimates
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(n = 368) (n = 365)
Surgery
Upper gastrointestinal 108 (29.4) 111 (30.4)
Lower gastrointestinal 168 (45.7) 165 (45.2)
Small bowel +/− pancreas 86 (23.4) 82 (22.5)
Urological or gynaecological involving gut 5 (1.4) 4 (1.1)
No surgery performed 1 (0.3) 3 (0.8)
Intervention
Cardiac monitor used 364 (98.9) 31 (8.5)
Dopexamine dose infused (mg) 18.9 (8.4) –
Intra-venous crystalloid (ml)
During surgery 1518 (1410) 2420 (1382)
6 h following surgery 565 (254) 670 (367)
Intra-venous colloid (ml)
During surgery 1465 (913) 708 (695)
6 h following surgery 642 (498) 226 (361)
Blood products (ml)
During surgery 141 (723) 95 (542)
6 h following surgery 80 (555) 10 (66)
Length of stay (days)
Critical care level 2 2.5 (3.7) 2.6 (3.4)
Critical care level 3 0.7 (2.4) 0.9 (3.8)
General surgical ward 10.3 (14.4) 11.4 (12.6)
Data presented as mean (SD) or n (%)
Fig. 1 Comparison of in-hospital costs up to 6 months between peri-operative cardiac output-guided haemodynamic therapy algorithm and
usual care
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sub-group of the later recruited patients (excluding the
first ten patients enrolled at each site), the intervention
was highly cost-effective, in line with the significant clin-
ical benefit in this sub-group (Pearse et al. 2014).
Lifetime cost-effectiveness analysis
The Kaplan-Meier curves suggest that, when time hori-
zon was extended beyond 6 months for those with sur-
vival data available, the probability of survival remained
similar between the two groups (Additional file 1: Figure
S2). When the alternative parametric specifications were
applied to the OPTIMISE data, goodness of fit (lowest
AIC) was similar in the various models (Additional file
1: Table S4). Compared to the general population, each
of the parametric survival models tended to predict
lower mortality up to year 2 and higher mortality after
year 2 (Additional file 1: Table S5). It was considered im-
plausible that the long-term mortality estimates of high-
risk surgical patients would be lower than that of the
general population. In the primary analysis, we therefore
applied age-gender matched general population death
rates after 6 months for each comparator. Of the alter-
native parametric functions, the Weibull was judged the
most plausible, and so, we applied this extrapolation in
sensitivity analysis. The small difference in long-term
quality of life between the OPTIMISE patients and the
general population in the first year following surgery was
assumed to decline to zero within the subsequent 2 years.
The intervention group patients, experienced more aver-
age lifetime QALYs and lower costs compared with usual
care patients, but again, these results were not statisti-
cally significant (Table 4). However, at the willingness to
pay threshold of £20,000 per QALY recommended in
the UK by NICE, the incremental net monetary benefit
of the intervention versus usual care was £4168 (−£3063
to £11,398) per patient, with a corresponding 87 % prob-
ability that the intervention is cost-effective when com-
pared with usual care (Fig. 2).
Value of information analysis
A conservative estimate of the size of the NHS patient
population eligible for the treatment was 270,503 eligible
NHS patients over a 5-year period. At a threshold of
£20,000 per QALY, the EVPI per patient is £239 and the
total EVPI for the effective population is £65 million
(Additional file 1: Figure S3).
Sensitivity analyses
Findings of the sensitivity analyses suggested that the
primary analysis was robust to alternative approaches
(Additional file 1: Table S6). The incremental net monet-
ary benefit varied between £3979 and £4289 across the
scenarios studied.
Discussion
The principal finding of this health economic evaluation
was that the peri-operative, cardiac output-guided,
haemodynamic therapy algorithm evaluated in the OP-
TIMISE trial has a high probability (87 %) of being cost-
effective at the willingness to pay threshold of £20,000
per QALY gained, recommended for use in the NHS by
NICE. Whereas most treatment innovations would be
expected to result in a net increase in healthcare costs,
lower critical care resource use and hospital stay resulted
in an average cost saving amongst the intervention pa-
tients. This observation is consistent with the suggestion
that improvements in the quality of peri-operative care
may improve patient outcomes whilst reducing health-
care costs. The pre-specified sub-group analysis on tim-
ing of recruitment showed that the intervention was
highly cost-effective in patients recruited later versus
earlier at each site. This result suggests that a learning
curve may have existed, consistent with expectations for
trials of complex interventions. The value to the NHS of
further research which would resolve the uncertainty
around this treatment is £65 million, which is far greater
than the likely cost of a definitive clinical trial.




Usual care Incremental effect
(n = 368) (n = 365)
Up to 6 months
Costs (£) 8574 (6304) 8974 (7217) −404 (−1313 to 505)
QALY 0.37 (0.11) 0.36 (0.12) 0.01 (0.00 to 0.02)
Incremental net benefit 580 (−378 to 1538)
Lifetime
Costs (£) 8574 (6304) 8974 (7217) −404 (−1313 to 504)
QALY 7.59 (3.34) 7.10 (3.60) 0.19 (−0.17 to 0.54)
Incremental net benefit 4168 (−3063 to 11,398)
Data presented as mean (SD) and mean (95 % confidence intervals)
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The findings of this analysis are consistent with those
of health economic analyses undertaken for previous
similar trials. Cost-effectiveness analyses of data from
two early single centre trials of peri-operative haemo-
dynamic therapy suggested that this treatment resulted
in a net reduction in healthcare costs and hence was
cost-effective (Fenwick et al. 2002; Guest et al. 1997).
However, more recent clinical trial data suggest that this
treatment may only deliver more modest improvements
in patient outcome and in some cases, provide only bor-
derline evidence of clinical effectiveness (Grocott et al.
2012; Pearse et al. 2014). Whilst the findings of health
economic simulations continue to suggest that peri-
operative haemodynamic therapy may be cost saving
and therefore cost-effective, these findings are sensitive
to the size of treatment effect (Bartha et al. 2012; Ebm et
al. 2014). Interestingly, economic evaluations of haemo-
dynamic therapy in patients with early severe sepsis also
indicate that the treatment may be cost-effective (Huang
et al. 2007; Jones et al. 2011; Talmor et al. 2008). However,
these analyses rely on the assumption of a strong treat-
ment effect whilst the outcome of the recent major ran-
domised trials suggest such protocols are associated
with little or no clinical benefit in patients with severe
sepsis (Peake et al. 2014; Yealy et al. 2014). Thus, whilst
the findings of the current work are consistent with
previous analyses, definitive evidence from a large clin-
ical effectiveness trial would be required to confirm the
economic impact of peri-operative cardiac output-
guided haemodynamic therapy. Importantly, the find-
ings of our value of information analysis show that such
a trial would represent excellent value for money, even
when confined to the NHS. This observation is consist-
ent with a previously published estimate of EVPI for
this treatment in elderly patients with hip fracture
(Bartha et al. 2013).
OPTIMISE was the largest trial of a peri-operative,
cardiac output-guided, haemodynamic therapy algorithm
conducted to date, which addressed several methodo-
logical limitations in the existing evidence base (Pearse
et al. 2014). The cost-effectiveness analysis was based on
trial data with lifetime cost-effectiveness results extrapo-
lated using appropriate methods and long-term survival
data. Quality of life was assessed longitudinally allowing
comparison of changes over time and comparison with
the age-gender-matched general population. We calcu-
lated the cost of decision uncertainty along with trad-
itional cost-effectiveness results. These findings will
therefore inform both clinical policy and priorities for
further research. However, costs and outcome data were
only collected for 6 months and the lifetime cost-
effectiveness analysis involved assumptions when ex-
trapolating these data. Nonetheless, sensitivity analyses
suggest the results were robust to alternative extrapola-
tion methods. Some follow-up data were missing for the
6-month endpoints, which we addressed with a recom-
mended approach of multiple imputation (Rubin 1987).
Whilst health economic data were prospectively in-
cluded in the trial dataset, the sample size calculation
was based on clinical outcomes. These results should be
interpreted in light of the fact that most trials are de-
signed to detect differences in clinical effectiveness ra-
ther than cost-effectiveness. Healthcare costs are more
variable than clinical outcomes, and economic evaluations
Fig. 2 Cost-effectiveness acceptability curve (all patient lifetime analysis) describing the probability that peri-operative cardiac output-guided
haemodynamic therapy is cost-effective for a range of decision makers’ willingness to pay thresholds per quality-adjusted life year (QALY) gained
when compared with usual peri-operative care
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may therefore lack statistical power. The primary objective
of economic evaluation is not hypothesis testing but
rather the estimation of incremental cost-effectiveness
measures along with appropriate representation of the un-
certainty surrounding those estimates. The results of this
economic evaluation show that confidence interval of in-
cremental costs, incremental QALY and incremental net
monetary benefit included zero, implying considerable
uncertainty surrounding these estimates. These uncer-
tainties were summarised with the recommended use of
cost-effectiveness acceptability curves, which conveys
to decision-makers the strength of evidence in support
of an intervention being cost-effective, at different
levels of willingness to pay for a QALY gain (e.g.
£20,000 or £30,000 per QALY).
Conclusions
For high-risk patients undergoing major gastrointestinal
surgery, the use of a peri-operative, cardiac output-
guided, haemodynamic therapy algorithm was associated
with an average cost reduction and is likely to be cost-
effective at the willingness to pay (cost per QALY)
threshold recommended for the UK by NICE. However,
a further large trial is still needed to confirm both the
clinical and cost-effectiveness of this treatment approach.
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